Hypertriglyceridemia and cardiovascular risk reduction

https://doi.org/10.1016/j.clinthera.2007.05.002Get rights and content

Abstract

Background:

Elevated triglyceride (TG) levels are prevalent among the US population, often occurring in persons who are overweight or obese, or who have type 2 diabetes or the metabolic syndrome. There is evidence that elevated TG levels may be a significant independent risk factor for coronary heart disease (CHD), particularly in women.

Objective:

This article reviews data on the epidemiology, associated risks, treatment, and prevention of hypertriglyceridemia, including recommended TG goals and available TG-lowering agents.

Methods:

MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids. The reference lists of relevant articles were examined for additional citations. Publications discussing the epidemiology of hypertriglyceridemia, CHD risk, treatment guidelines for lipid management, clinical trials involving TG-lowering drugs, and outcomes for lipid-modifying therapies were selected for review.

Results:

Concern over the increasing rate of hypertriglyceridemia and its deleterious health consequences is reflected in the most recent National Cholesterol Education Program guidelines. Several lipid-lowering agents are available, including statins, fibrates, niacin, thiazolidinediones, and prescription omega-3 fatty acids. Clinical trials of these drugs have reported lowering of TG by 7% to 50%. Along with lifestyle changes, the use of combination pharmacotherapy to reduce lipid levels (including TG) may be an effective strategy in patients with dyslipidemia.

Conclusion:

Use of strategies to manage TG levels, along with low-density lipoprotein cholesterol levels, is warranted to help reduce the risk of CHD.

References (97)

  • JonesP. et al.

    Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study)

    Am J Cardiol.

    (1998)
  • SteinE.A. et al.

    Comparison of statins in hypertriglyceridemia

    Am J Cardiol.

    (1998)
  • CalabresiL. et al.

    Omacor in familial combined hyperlipidemia: Effects on lipids and low density lipoprotein subclasses

    Atherosclerosis

    (2000)
  • CannerP.L. et al.

    Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin

    J Am Coll Cardiol.

    (1986)
  • DormandyJ.A. et al.

    Secondary prevention of macro vascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial

    Lancet

    (2005)
  • WilsonP.W. et al.

    Prediction of coronary heart disease using risk factor categories

    Circulation

    (1998)
  • HokansonJ.E. et al.

    Plasma triglyceride level is a risk factor for cardiovascular disease independent of highdensity lipoprotein cholesterol level: A meta-analysis of population-based prospective studies

    J Cardiouasc Risk

    (1996)
  • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

    Circulation

    (2002)
  • SemposC.T. et al.

    Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program AdultTreatment Panel

    JAMA

    (1993)
  • FordE.S. et al.

    Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey

    JAMA

    (2002)
  • AlexanderC.M. et al.

    NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older

    Diabetes

    (2003)
  • AssmannG. et al.

    The emergence of triglycerides as a significant independent risk factor in coronary artery disease

    Eur Heart J.

    (1998)
  • JeppesenJ. et al.

    Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study

    Circulation

    (1998)
  • Abdel-MaksoudM.F. et al.

    The complex role of triglycerides in cardiovascular disease

    Semin Vasc Med.

    (2002)
  • BrewerH.B.

    Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease

    Am J Cardiol

    (1999)
  • GianturcoS.H. et al.

    Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceriderich lipoproteins to their unique human monocyte-macrophage receptor

    Arterioscler Thromb Vasc Biol.

    (1998)
  • McNamaraJ.R. et al.

    Change in LDL particle size is associated with change in plasma tri glyceride concentration

    Arterioscler Thromb.

    (1992)
  • SchaeferE.J. et al.

    Elevated remnant like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study

    Diabetes Care

    (2002)
  • AustinM.A. et al.

    Atherogenic lipoprotein phenotype. A proposed genetic mark er for coronary heart disease risk

    Circulation

    (1990)
  • AustinM.A. et al.

    Low-density lipoprotein subclass patterns and risk of myo cardial infarction

    JAMA

    (1988)
  • LorenzoC. et al.

    The metabolic syndrome as predictor of type 2 diabetes: The San Antonio Heart Study

    Diabet Care

    (2003)
  • LakkaH.M. et al.

    The metabolic syndrome and total and cardiovascular dis ease mortality in middle-aged men

    JAMA

    (2002)
  • HaffnerS.M. et al.

    Dyslipidemia management in adults with diabetes

    Diabetes Care

    (2004)
  • DunbarR.L. et al.

    Demystifying triglycerides: A practical approach for the clinician

    Cleve Clin J Med

    (2005)
  • IsomaaB. et al.

    Cardiovascular morbidity and mortality associated with the metabolic syndrome

    Diabetes Care

    (2001)
  • FlegalK.M. et al.

    Prevalence and trends in obesity among US adults, 1999–2000

    JAMA

    (2002)
  • Diabetes statistics. Available at: www. diabetes.org/diabetes-statistics.jsp. Accessed April 13,...
  • SuviolahtiE. et al.

    Unraveling the complex genetics of familial combined hyperlipidemia

    Ann Med.

    (2006)
  • GenestJ.J. et al.

    Familial lipoprotein disorders in patients with premature coronary artery disease

    Circulation

    (1992)
  • HavelR.J. et al.

    Management of primary hyperlipidemia

    N Engl J Med.

    (1995)
  • RubinsH.B. et al.

    Diabetes, plasma insulin, and cardiovascular disease: Subgroup analy sis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)

    Arch Intern Med.

    (2002)
  • NashD.T.

    Cardiovascular risk beyond LDL-C levels. Other lipids are performers in cholesterol story

    Postgrad Med.

    (2004)
  • ReavenG.M.

    The insulin resistance syndrome: Definition and dietary approaches to treatment

    Annu Rev Nutr.

    (2005)
  • FAQ-"better" fats (monounsaturated and polyunsaturated fats). Available at:...
  • HeK. et al.

    Accumulated evidence on fish consumption and coronary heart disease mortality: A meta-analysis of cohort studies

    Circulation

    (2004)
  • MillerM.

    Why triglycerides need to be aggressively managed: A guide for physicians

    Cardiovasc Rev Rep

    (2003)
  • StaelsB. et al.

    Mechanism of action of fibrates on lipid and lipoprotein metabolism

    Circulation

    (1998)
  • JinF.Y. et al.

    Niacin decreases removal of highdensity lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport

    Arterioscler Thromb Vasc Biol

    (1997)
  • Cited by (117)

    • Bioactive Compounds of Winery by-products: Extraction Techniques and their Potential Health Benefits

      2022, Applied Food Research
      Citation Excerpt :

      Hyperlipidemia is a term that refers to elevated levels of triglycerides or cholesterol in the blood. Micro and macro vascular complications such as cerebrovascular, microangiopathy, cardiovascular and other metabolic disorders are consequences of long term hyperlipidemia (Jacobson et al., 2007). Various studies were conducted to demonstrate the role of grape seed extract in controlling postprandial hyperlipidemia.

    View all citing articles on Scopus
    View full text